Show simple item record

dc.contributor.authorHelland, Øysteinen_US
dc.contributor.authorPopa, Mihaela Luciaen_US
dc.contributor.authorVintermyr, Olav Karstenen_US
dc.contributor.authorMolven, Andersen_US
dc.contributor.authorGjertsen, Bjørn Toreen_US
dc.contributor.authorBjørge, Lineen_US
dc.contributor.authorMcCormack, Emmeten_US
dc.description.abstractPurpose: Preclinical models of epithelial ovarian cancer have not been exploited to evaluate the clinical standard combination therapy of surgical debulking with follow-up chemotherapy. As surgery is critical to patient survival, here we establish a combined surgical/chemotherapy xenograft model of epithelial ovarian cancer and demonstrate its translational relevance. Experimental Design: SKOV-3luc+ ovary cancer cells were injected topically into the ovaries of immunodeficient mice. Disease development and effect of clinical standard treatment including hysterectomy, bilateral salpingoophorectomy and removal of metastasis with follow up chemotherapy (carboplatin 12 mg/kg + paclitaxel 15 mg/kg) was evaluated by clinical parameters. Tumor burden was quantified by bioluminescence imaging (BLI). Results: The xenograft ovarian tumors developed were poorly differentiated and multicystic and the disease disseminated into the peritoneal cavity. When compared to the controls with a mean survival time of 4.9 weeks, mice treated with surgery and chemotherapy, surgery or chemotherapy demonstrated significantly improved mean survival of 16.1 weeks (p = 0.0008), 12.7 weeks (p = 0.0008), or 10.4 weeks (p = 0.008), respectively. Conclusion: Combined surgical intervention and adjuvant chemotherapy was demonstrated for the first time in an orthotopic xenograft model of ovarian cancer. Similar to observation in human studies the combined approach resulted in the longest medial survival time, advocating application of this strategy in future preclinical therapeutic development for this disease.en_US
dc.publisherThe University of Bergeneng
dc.rightsAttribution CC BYeng
dc.titleFirst in-mouse development and application of a surgically relevant xenograft model of ovarian carcinomaen_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2014 Helland et al.
dc.source.journalPLoS ONE
dc.subject.nsiVDP::Medical sciences: 700::Clinical medical sciences: 750::Oncology: 762eng
dc.subject.nsiVDP::Medisinske fag: 700::Klinisk medisinske fag: 750::Onkologi: 762nob

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY